Vyndaqel Market: Market Size & Forecast 2026

The Vyndaqel market encompasses the global commercial ecosystem for tafamidis meglumine and tafamidis, pharmaceutical products that stabilize transthyretin (TTR) tetramers to slow or prevent the formation of amyloid fibrils that deposit in organs. Originally approved in 2011 for ATTR-PN, the drug gained a landmark approval in 2019 for ATTR-CM, significantly expanding its addressable patient population. The market is valued at approximately $3.5 billion in 2025, driven by sales across North America, Europe, and growing markets in Asia-Pacific and Latin America.

• •Tafamidis addresses two primary indications: transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) and transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP)
• •Pfizer is the originator and primary commercial developer of Vyndaqel, having acquired the rights through its acquisition of FoldRx Pharmaceuticals in 2010
• •The market spans branded drug sales, patent lifecycle management, biosimilar/generic anticipation, and pipeline competing TTR stabilizers

The primary growth engine for the Vyndaqel market is the rising and aging global population, which increases the prevalence of both wild-type and hereditary ATTR conditions that historically went underdiagnosed. Improved diagnostic technologies, including nuclear imaging and genetic screening, are enabling earlier and more widespread identification of ATTR-CM and ATTR-PN patients who can benefit from treatment. Additionally, robust Phase III clinical data demonstrating reductions in mortality and cardiovascular hospitalizations in ATTR-CM patients has established Vyndaqel as a standard-of-care therapy, driving physician adoption and formulary inclusion.

• •Expanding geographic regulatory approvals, including emerging-market authorizations, continue to unlock new revenue pools beyond the initial approval regions
• •Growing clinical evidence and guideline endorsements from cardiology and neurology societies reinforce Vyndaqel's position as a first-line transthyretin amyloidosis therapy
• •Demographic aging trends, particularly the growing population over 65 at highest risk for wild-type ATTR-CM, expand the eligible treatment population

The market is segmented by disease type into ATTR-CM and ATTR-PN/FAP, with ATTR-CM representing the larger and faster-growing segment due to the significantly higher prevalence of wild-type ATTR-CM among elderly populations compared to the rarer hereditary form of polyneuropathy. North America commands the largest regional share due to high diagnosis rates, favorable reimbursement frameworks, and early market access, while Europe follows closely with strong healthcare system adoption. Asia-Pacific and Latin America represent emerging growth regions where increasing healthcare infrastructure investment and improving diagnostic capabilities are driving market penetration.

• •ATTR-CM dominates the market, while ATTR-PN (familial amyloid polyneuropathy) serves a smaller but steadily growing patient cohort concentrated in regions with higher genetic prevalence such as Portugal, Sweden, and Japan
• •North America holds the largest market share, with the United States representing the primary revenue contributor due to widespread payer coverage under Medicare and commercial insurance
• •Payer segmentation includes government payers, private insurers, and out-of-pocket markets, with reimbursement policies heavily influencing patient access and prescribing volumes across countries

What are the recent trends and outlook?

The Vyndaqel market is expected to sustain approximately 7.8% annual growth through the early 2030s, supported by continued geographic expansion, broadening diagnostic screening programs, and the accumulation of longer-term clinical outcome data. A key near-term trend is patent expiry risk, which will introduce generic competition and pressure pricing in major markets, potentially reshaping revenue models for Pfizer. Long-term, the market may see a shift toward combination therapies or next-generation TTR-modulating agents that offer improved efficacy, dosing convenience, or cost profiles, particularly in ATTR-CM where large patient populations exist.

• •Patent expiration events in key markets (notably the United States and Europe) will introduce generic tafamidis competition, likely within the patent lifecycle horizon, compressing branded pricing and market value unless offset by volume growth
• •Earlier-stage disease intervention and screening-based treatment initiation are emerging clinical trends that could substantially expand the total addressable ATTR patient population
• •Pipeline candidates from multiple biotech companies targeting TTR through novel mechanisms, including small-molecule stabilizers and CRISPR-based gene editing approaches, could diversify or fragment the therapeutic landscape by the early 2030s